Literature DB >> 7983004

Insulin-inducible changes in insulin receptor mRNA splice variants.

S M Sell1, D Reese, V M Ossowski.   

Abstract

Alternative splicing of insulin receptor pre-mRNA has been shown to be regulated in a tissue-specific and developmental manner. We investigated whether the receptor ligand might regulate the relative distribution of alternatively spliced mRNA in insulin-sensitive cells and found that changes in the relative expression of the two alternatively spliced insulin receptor RNA isotypes expressed in hepatocytes are regulated by insulin. In addition, we observed significant differences (p < or = 0.001) in insulin receptor isotype expression in subjects who were hyperinsulinemic and insulin-resistant versus subjects who were insulin-sensitive. These results support a role for insulin in the regulation of the relative expression of alternatively spliced mRNA expressed in insulin-responsive cells and tissues.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7983004

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  11 in total

1.  The interaction and colocalization of Sam68 with the splicing-associated factor YT521-B in nuclear dots is regulated by the Src family kinase p59(fyn).

Authors:  A M Hartmann; O Nayler; F W Schwaiger; A Obermeier; S Stamm
Journal:  Mol Biol Cell       Date:  1999-11       Impact factor: 4.138

2.  Acute regulation by insulin of phosphatidylinositol-3-kinase, Rad, Glut 4, and lipoprotein lipase mRNA levels in human muscle.

Authors:  M Laville; D Auboeuf; Y Khalfallah; N Vega; J P Riou; H Vidal
Journal:  J Clin Invest       Date:  1996-07-01       Impact factor: 14.808

Review 3.  Insulin receptor/IRS-1/PI 3-kinase signaling system in corticosteroid-induced insulin resistance.

Authors:  F Folli; M J Saad; C R Kahn
Journal:  Acta Diabetol       Date:  1996-09       Impact factor: 4.280

4.  Evidence for a role of insulin in hepatocytic differentiation of human hepatoma BC1 cells.

Authors:  S Kang-Park; J Capeau; A Munier; M Caron; D Glaise; C Guguen-Guillouzo; G Cherqui; O Lascols
Journal:  Endocrine       Date:  1995-09       Impact factor: 3.633

Review 5.  A new link between epigenetic progenitor lesions in cancer and the dynamics of signal transduction.

Authors:  Winston Timp; Andre Levchenko; Andrew P Feinberg
Journal:  Cell Cycle       Date:  2009-02-03       Impact factor: 4.534

6.  Increased expression of low-affinity insulin receptor isoform and insulin/insulin-like growth factor-I hybrid receptors in term placenta from insulin-resistant women with gestational hypertension.

Authors:  H Valensise; Y Y Liu; M Federici; D Lauro; D Dell'anna; C Romanini; G Sesti
Journal:  Diabetologia       Date:  1996-08       Impact factor: 10.122

7.  Reduced insulin-like growth factor I receptor and altered insulin receptor isoform mRNAs in normal mucosa predict colorectal adenoma risk.

Authors:  M Agostina Santoro; Sarah F Andres; Joseph A Galanko; Robert S Sandler; Temitope O Keku; P Kay Lund
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2014-07-13       Impact factor: 4.254

8.  Chronic primary hyperinsulinaemia is associated with altered insulin receptor mRNA splicing in muscle of patients with insulinoma.

Authors:  P Sbraccia; M D'Adamo; F Leonetti; S Caiola; P Iozzo; A Giaccari; A Buongiorno; G Tamburrano
Journal:  Diabetologia       Date:  1996-02       Impact factor: 10.122

9.  Tissue-specific expression of insulin receptor isoforms in obesity/type 2 diabetes mouse models.

Authors:  Noah Moruzzi; Francesca Lazzeri-Barcelo; Ismael Valladolid-Acebes; Tilo Moede; Meike Paschen; Barbara Leibiger; Per-Olof Berggren; Ingo B Leibiger
Journal:  J Cell Mol Med       Date:  2021-03-19       Impact factor: 5.310

10.  Aberrant liver insulin receptor isoform a expression normalises with remission of type 2 diabetes after gastric bypass surgery.

Authors:  Vinko Besic; Hongjun Shi; Richard S Stubbs; Mark T Hayes
Journal:  PLoS One       Date:  2015-03-05       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.